Table 3.

CAPRIE—Unadjusted and Adjusted^* EHRs (95% CI) for the Primary Efficacy End Point by PPI Use (Time‐Dependent Variable)

	Clopidogrel				Aspirin				P Value for Interaction*
	PPI	No PPI	Unadjusted EHR (95% CI)	Adjusted EHR (95% CI)	PPI	No PPI	Unadjusted EHR (95% CI)	Adjusted EHR (95% CI)
IS, MI, vascular death	14.0% (57/408)	9.6% (882/9191)	2.66 (1.94 to 3.63), P<0.001	2.39 (1.74 to 3.28), P<0.001	9.4% (45/479)	10.7% (975/9107)	1.17 (0.78 to 1.76), P=0.439	1.04 (0.70 to 1.57), P=0.834	0.001

CAPRIE indicates Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events; EHR, estimated hazard ratio; PPI, proton pump inhibitor; MI, myocardial infarction; RIND, reversible ischemic neurological deficit; IS, ischemic stroke.

^*Adjusted model includes race, diabetes, hypercholesterolemia, congestive heart failure, cardiomegaly, atrial fibrillation, stable angina, unstable angina, previous MI, TIA, RIND, previous IS, intermittent claudication, and leg amputation. Both models are stratified by qualifying condition, and the adjusted model is additionally stratified by 5 propensity score strata.

^*Interaction analysis performed on adjusted comparison.